



Lowther, K., Harding, R., Simms, V., Gikaara, N., Ahmed, A., Ali, Z., Kariuki, H., Sherr, L., Higginson, I. J., & Selman, L. (2018). Effect of participation in a randomised controlled trial of an integrated palliative care intervention on HIV-associated stigma. *AIDS Care*.  
<https://doi.org/10.1080/09540121.2018.1465176>

Peer reviewed version

Link to published version (if available):  
[10.1080/09540121.2018.1465176](https://doi.org/10.1080/09540121.2018.1465176)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Taylor and Francis at <https://www.tandfonline.com/doi/full/10.1080/09540121.2018.1465176>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**Effect of participation in a randomised controlled trial of an  
integrated palliative care intervention on HIV-associated stigma**

Authors:

**Keira LOWTHER (PhD)** (Corresponding author)

Department of Palliative Care and Rehabilitation, King's College London, Cicely  
Saunders Institute, Bessemer Road, SE5 9PJ, UK.

Keira.Lowther@dartington.org.uk

+44 (0) 207 848 5518

**Richard HARDING (PhD)**

King's College London, Cicely Saunders Institute, Department of Palliative Care and  
Rehabilitation, Bessemer Road, SE5 9PJ, UK.

**Victoria SIMMS (PhD)**

London School of Hygiene and Tropical Medicine, London, Keppel Street, London,  
WC1E 7HT. UK.

**Nancy GIKAARA (BA)**

Kenyan Hospice Palliative Care Association, Nairobi, Kenya, P.O Box 20854, 00202,  
Nairobi, Kenya.

**Aabid AHMED (MD)**

Bomu Hospital, Off Airport Road, Soweto, P.O. BOX 95683, Mombasa, Kenya.

**Zipporah ALI (MD)**

Kenya Hospices and Palliative Care Association, P.O Box 20854, 00202, Nairobi

23 **Hellen KARIUKI (PhD)**

24 University of Nairobi, Department of Medical Physiology, Chiromo Campus, PO BOX  
25 30197 (00100) Nairobi, Kenya.

26 **Lorraine SHERR (PhD)**

27 University College London, Dept of Infection and Population Health, Rowland Hill  
28 Street, London NW32PF, UK

29 **Irene J HIGGINSON (PhD)**

30 King's College London, Cicely Saunders Institute, Department of Palliative Care and  
31 Rehabilitation, Bessemer Road, SE59PJ, UK.

32 **Lucy SELMAN (PhD)**

33 Population Health Sciences, Bristol Medical School, University of Bristol, Whatley  
34 Road, Bristol BS8 2PS. UK.

35 \*corresponding author

36

37 Short title/running head: Resistance to HIV-associated stigma

38 Word count 3599

## Abstract

We conducted in Kenya a mixed-methods randomised controlled trial (RCT) of a nurse-led palliative care intervention integrated with anti-retroviral therapy (ART) provision for the management of HIV. Here we report qualitative findings showing increased resistance to HIV-associated stigma among trial participants. A mixed method design was chosen to enable identification of the active ingredients of the intervention and exploration of participants' experiences of receiving the intervention. The RCT was conducted from July 2011 to November 2012 in a community hospital in the city of Mombasa, Kenya, with a sample of 120 adults with HIV on ART. Thirty participants were purposively selected to take part in a qualitative exit interview, based on study arm and mental health outcome.

Inductive thematic analysis revealed increased resistance to HIV-associated stigma in both the intervention and control groups. Specifically, patients in both groups described benefit from the social support, compassionate care, and open and respectful communication they received through study participation. Participants described improved self-image, increased access to social agency, and increased resistance to HIV-associated stigma. Our findings suggest that there is potential to increase resistance to stigma through simple mechanisms of support, compassion, and improved communication in routine care. The self-reported impact of trial participation on stigma also has implications for future trials in populations in resource-constrained settings where stigma is common.

Keywords: HIV/AIDS; Stigma; Shame; Palliative Care; Kenya;

## 62    **Introduction**

63    Stigma was defined by Goffman in 1963 as a mark of social disgrace, where the  
64    stigmatised are excluded from social acceptance and are socially devalued  
65    (Goffman, 1963). Although commonly understood at the individual level (Herek,  
66    Saha, & Burack, 2013a), or the macro-societal level (Parker & Aggleton, 2003), an  
67    appreciation of both acknowledges how social processes become part of a  
68    stigmatised other's identity making resistance at an individual level very difficult  
69    (Catherine Campbell & Deacon, 2006). The persistence of HIV associated stigma, is  
70    a threat to progress in the control of HIV internationally (Stangl & Grossman, 2013), a  
71    barrier to testing (Dapaah & Senah, 2016), prevention of mother-to-child transmission  
72    (Turan & Nyblade, 2013), and, once diagnosis is confirmed, stigma remains a barrier to  
73    PLWH accessing adequate healthcare (Bogart et al., 2013; Dasgupta, Sullivan, Dasgupta,  
74    Saha, & Salazar, 2013). It is also associated with non-adherence to antiretroviral  
75    therapy (ART), increasing the risk of viral resistance (Mhode & Nyamhanga, 2016;  
76    Sweeney & Venable, 2016).

77    Community members often distance themselves from PLWH due to stigma (C.  
78    Campbell, Foulis, Maimane, & Sibiya, 2005; Visser & Sipsma, 2013), denying their own risk  
79    of contracting HIV, putting themselves at increased risk of transmission and delayed  
80    diagnosis (Nyblade et al., 2003). Among PLWH, the social ramifications of disclosure  
81    increase the risk of transmission through reluctance to openly take medications or  
82    negotiate condom use with a sexual partner (Mbonu, van den Borne, & De Vries, 2009;  
83    Turan & Nyblade, 2013).

84    In addition to these public health concerns, there is evidence that people  
85    experiencing HIV-associated stigma report less healthcare utilization, and poorer

physical health (Bennett, Traub, Mace, Juarascio, & O'Hayer, 2016; Herek, Saha, & Burack, 2013b). HIV-associated stigma also manifests as social isolation and rejection (C. Campbell et al., 2005; Owolabi et al., 2012), increasing depression (Palmer et al., 2011; Sumari-de Boer, Sprangers, Prins, & Nieuwkerk, 2012), anxiety (Adewuya et al., 2009) and low self-esteem (Visser & Sipsma, 2013). A recent study suggests that this relationship between HIV-associated stigma and psychological well-being may be mutually reinforcing (Miller et al., 2016).

The international community struggles to identify stigma reduction interventions that are effective for HIV-related health outcomes (Stangl, Lloyd, M Brady, Holland, & Baral, 2013). Studies are often methodologically weak due to predominant use of locally-created and/or un-validated outcome measures, which inhibit interpretation and comparison across studies (Sengupta, Banks, Jonas, Miles, & Smith, 2011; Stangl et al., 2013).

HIV-associated stigma also presents high costs for society (direct and indirect effects of stigma reduction have been valued at a potential \$1000 per point on the Berger Stigma scale) (Brent, 2016).

We conducted a randomised controlled trial (RCT) of a nurse-led palliative care intervention for PLWH established on ART in Mombasa, Kenya (Lowther et al., 2012, 2014, 2015). In qualitative exit interviews, the themes of stigma, resistance to stigma, and the effects of participation in the research, emerged inductively as highly salient to participants. In this paper, we aim to describe experiences of stigma and stigma resistance among PLWH enrolled in the trial, and to draw out implications for clinical practice and research.

## Materials and methods

The Treatment Outcomes in Palliative Care (TOPCare) study was an RCT of a nurse-led, integrated palliative care intervention for HIV positive patients conducted in a clinic in Mombasa, Kenya. The trial had an embedded qualitative component with a sequential, explanatory design (Ivankova, Creswell, & Stick, 2006). Study methodology is reported elsewhere (Lowther et al., 2012), as are details of recruitment, follow up and missing data (Lowther et al., 2014), and results of the trial (Lowther et al., 2015). We found the intervention had significant positive effect in terms of mental health and well-being, but no effect on pain or physical outcomes (Lowther et al., 2015).

The intervention consisted of 4 months of palliative care integrated into patients' routine HIV outpatient care. It was delivered by two experienced HIV clinic nurses who received two weeks' specialist training in palliative care from the Kenyan Hospice and Palliative Care Association and clinical support and mentoring from local hospice nurses. The training covered pain management, symptom management, nutrition, psychosocial and spiritual assessment and care, breaking bad news, ethical and legal issues, and bereavement. Participants in the intervention arm received a minimum of 7 appointments (approximately 45 minutes long) with one of the two intervention nurses. The nurse delivered person-centred care which included a holistic assessment of emotional, spiritual, social and physical well-being, patients' understanding of HIV, and ability to maintain treatment adherence. This assessment informed care delivery, with hospice referral for complex cases of pain and symptom management. Control arm participants received standard care in the Comprehensive Care Clinic (CCC) at the study site, which consisted of monthly

appointments usually lasting 5-7 minutes. They were seen by HIV clinic nurses with similar levels of experience but without the additional training.

### *Sampling*

Participants who met the inclusion criteria for the wider trial were aged  $\geq 18$ , HIV positive and on ART for more than one month, and reported moderate to severe pain or symptoms lasting at least 2 weeks, as measured by the African Palliative Care Association Palliative Outcome Scale (APCA POS (Harding et al., 2010)). The sub-sample recruited to the qualitative component of the study was purposively selected based on study arm allocation and individual quantitative response to participation in the trial. Participants from the intervention arm were over-sampled (10 control /20 intervention) to enable in depth exploration of the active ingredients and mechanism of action of the intervention (data to be reported elsewhere). Sampling was in line with a sequential explanatory mixed methods design: we purposively selected participants to achieve a maximum variation sample based on individuals' clinical response to the intervention. Response was measured using the Medical Outcomes Survey – HIV Mental Health Summary Score (MOS-HIV MHSS), the mental health subscale of a well-validated, disease-specific quality of life measure (Wu, 1999). A change of 10 points on the MOS-HIV MHSS is considered clinically significant (Wu, 1999). Participants were categorised as “improving” if they improved by  $\geq 10$  points during the four-month study period, “static” if there was  $< 10$  points change in either direction, and “deteriorating” if they decreased by  $> 10$  points over the study period. A sample size of thirty qualitative interviews was chosen to balance opportunity for data saturation with feasibility of in-depth analysis (Sandelowski, 1995).



## *Data collection*

Data collection in both groups involved five quantitative data collection appointments at monthly intervals, with selected participants invited to take part in a qualitative interview from 1-8 months post trial exit.

The same Kenyan researcher (NG) who collected the quantitative data throughout the RCT conducted the qualitative exit interviews. The researcher was skilled and experienced in qualitative research, provided with study-specific training, and bilingual in English and Swahili. The interviews lasted approximately 45 minutes, and were guided by a semi-structured topic guide developed by the study group. The topic guide included questions about participants' physical, psychological, social and spiritual well-being before, during and after the study, in line with the holistic nature of the palliative care approach (WHO, 2013). Participants were also asked about their experiences of participating in the study, and, if allocated to the intervention arm, their perceptions of the differences between the two models of care (intervention vs standard care).

The interviews were conducted in a private location at the study site in either English, Swahili or both, depending on participant preference. Participants were welcomed into the study setting, and given refreshments to demonstrate hospitality and respect. The interviews were digitally recorded, transcribed and translated into English (where needed) by an experienced translator. Translations were quality checked by the researcher against the interview recordings, and amended if inaccuracies or errors were identified.

## *Analysis*

Transcripts were analysed thematically using a combination of deductive and inductive coding (Braun & Clarke, 2006). Deductive themes were identified according to the domains of well-being integral to palliative care (physical, psychological, social and spiritual), while additional themes emerged inductively. Themes were defined as codes or collections of codes containing elements which represented a patterned response or concept (Barbour, 2013). Following Barbour, the following questions were posed to identify themes, with constant reference to the study objectives: “Which codes are repeated? How do they relate to each other? Do these codes relate as sub-themes or associates in that they occur simultaneously?” (Barbour, 2013). Once identified, themes were organised hierarchically into major themes and sub-themes, according to their meaning and relationship to each other, to structure and reduce the volume of data. Major themes were those with high levels of salience and significance, in terms of understanding the therapeutic aspects of the intervention and their repetition across the dataset. Analysis was managed using NVivo 9 software. Findings are presented using anonymised illustrative quotes, annotated with the participant’s gender, age and intervention arm (Tables 2 and 3, cross-referenced in the text).

## *Ethics*

Ethical approval was provided by King’s College London Research Ethics Committee (BDM/10/11-31) and the Kenyan Medical Research Institute (KEMRI/RES/7/3/1). All patients gave written informed consent (if the participant was unable to read or write, the information sheet was read aloud and a thumb print given to indicate consent).

## Results

### *Sample characteristics*

30 participants were interviewed; no one approached declined. Participants were similar to the wider trial sample in terms of clinical and demographic characteristics (Table 1). Mean age was 39.1, with a mean of 2.4 children and 3.2 financial dependants. Most were women (80%, n=24), and two-thirds (67.7%, n=20) completed primary school as their highest educational attainment. Interviews were conducted from one to eight months after trial exit (mean 4.2 months). The research team judged that data saturation was reached in that no new themes emerged from the analysis of later interviews.

[INSERT TABLE 1 NEAR HERE]

### *Findings*

Stigma arose inductively in the data as an important characteristic of participants' experience of living with HIV, described by 25 of the 30 participants. Findings regarding stigma are presented in two themes: experience of HIV-associated stigma, and effects on HIV-associated stigma of participation in the trial.

#### *Experience of HIV-associated stigma (Table 2)*

When asked to describe their well-being before study participation, many participants described the experience of stigma indirectly, in terms of a fear of disclosure of their HIV diagnosis. They anticipated that this would lead to being shamed, socially isolated or discriminated against (quote 1). Participants reported hiding their status behind diagnoses which were more socially acceptable to their networks, for example saying they had tuberculosis (TB). The HIV positive diagnosis led some

participants to self-hatred and suicidal ideation. One participant described how internalised stigma, from cultural norms associating HIV with immorality, created an identity crisis (quote 2). Once they disclosed their HIV status to others, some participants reported experiencing anger and blame from their families and other community members (quote 3).

Experiencing this enacted stigma or discrimination against PLWH, either directly or vicariously, discouraged participants from disclosing their status, which led to increased isolation and suffering. Social isolation was a major cause of sadness; friends from before they were diagnosed had left, increasing their sense of vulnerability and isolation (quote 4)

[INSERT TABLE 2 NEAR HERE]

### *Effects of participation in research on HIV-associated stigma (Table 3)*

During the counselling received in clinical appointments, intervention participants were encouraged by the study nurses to see themselves as normal, just like any other person. This was reported to improve self-esteem, self-image and acceptance, and help participants resist internalised stigma (quotes 5-7). Some intervention arm participants described dramatic changes in their outlook, from suicidal to positive (quote 8). However, the beneficial effects of participation also extended to those PLWH in the control arm, with both groups of participants describing the therapeutic effects of their interactions with the study team (quotes 9, 10)

Participants built a trusting relationship with the researcher who administered the study questionnaires, owing to the compassion they witnessed, and her non-judgemental and open communication style. They described how this way they were treated, enabled them to rebuild a positive self-image (quotes 11, 12). This change in

248 self-regard was often described as a shift in seeing themselves as normal rather  
249 than abnormal, and worthy of respect, social interest and engagement (quotes 13,  
250 14). Participants described how, through this growth in self-esteem, they were more  
251 able to reject stigmatising messages, and became confident in disclosing their HIV  
252 positive status to their close communities (quote 15). Being treated as a normal  
253 person by a health care practitioner was in stark contrast to the advice received by  
254 one participant attending the standard clinic, who reported she was advised to  
255 'behave normally' when she received her diagnosis, in case people realised that she  
256 was HIV positive (quote 16).

257 One of the most powerful aspects of participation in reducing internalised stigma was  
258 being given the space and permission to talk (quotes 17, 18). Some participants  
259 clearly attributed the effect to the process of completing the outcome measurements  
260 (quotes 19, 20). Because of participation in the study and the support they received  
261 through attending data collection appointments, some participants made concrete  
262 changes to their social situations (quote 21). Others became activists in less public  
263 ways, making themselves available to others for counselling and support, particularly  
264 those who had recently received their diagnosis. They described having the  
265 confidence and self-belief to act normally, interacting with their communities  
266 accordingly, and ignoring the stigmatising responses they had previously anticipated  
267 and feared. These newly created identities as 'activists' were socially acceptable and  
268 added purpose to participants' lives participants (quotes 22, 23).

269 [INSERT TABLE 3 NEAR HERE]

## 270 Discussion

271 The findings of this study demonstrate the therapeutic value of a relationship  
272 characterised by compassionate care, social support, and open and non-  
273 judgemental communication. While intervention group participants described benefit  
274 from their appointments with the study nurse, participants in both groups described  
275 the way that simply participating in the trial's data collection procedures helped them  
276 to increase their resistance to the stigma associated with HIV.

277 The researcher completed standardised patient reported outcome measures with  
278 each participant at regular intervals over a four-month time-period. She had no  
279 therapeutic remit or training, yet participants clearly described therapeutic benefit,  
280 including increasing ability to resist stigma. We can see two possible reasons for  
281 this. Firstly, the act of being asked questions about their well-being and problems  
282 may have served to acknowledge their importance. Secondly, being accepted and  
283 treated with respect may have helped patients renegotiate a positive self-identity.

284 This second hypothesis is supported by other studies of HIV-associated stigma  
285 (Goudge, Ngoma, Manderson, & Schneider, 2009; Soskolne, 2003). In a study in South  
286 Africa, women living with HIV described how, given time, they were able to negotiate  
287 a new positive self-identity which helped them cope with anxiety and the stigma of  
288 their HIV diagnosis (Soskolne, 2003). The work of Goudge et al. (2009) describes the  
289 crucial role of social support – the very thing lacking when stigma is present and  
290 powerful - in this process (Goudge et al., 2009). They found that through social  
291 support, PLWH were able to express their emotions, make sense of their diagnosis  
292 and move towards a problem-solving approach toward managing their health,

293 whereas those with less support were less able to adjust and cope (Goudge et al.,  
294 2009).

295 The shift observed in our participant group can also be understood through the lens  
296 of shame and shame resistance theories. Van Vliet's theory of shame resistance  
297 states that to improve the affected person's self-concept individuals must undergo a  
298 process of reconstruction, rebuilding a new identity in response to a shaming  
299 experience (Van Vliet, 2008). She describes the five sub-processes this involves:  
300 connecting, refocusing, accepting, understanding and resisting (Van Vliet, 2008).  
301 These sub-processes appear to mirror our participants' descriptions of their  
302 experience of participating in the trial. Connecting and refocusing are described  
303 when patients talk of the social support they received from the research team.  
304 Acceptance can be seen in their descriptions of learning to accommodate their HIV  
305 status, in part through the acceptance they experienced from the research team.  
306 Participants receiving the intervention described being treated as normal people, told  
307 that they were normal and advised that should treat themselves accordingly, as  
308 particularly potent aspects of the intervention. Central to acceptance was coming to  
309 understand that anyone, even morally 'good' people, can get HIV. The final sub-  
310 process in Van Vliet's theory is resistance. Using their reformed identity and renewed  
311 positive self-image as 'good' or 'normal' people, some participants expressed stigma  
312 resistance through becoming an activist or supporter of other PLWH. Others  
313 expressed their resistance through reaching out to rejecting family members,  
314 deciding not to be ashamed, and widely disclosing their HIV status.

315 Our findings regarding reforming identity reflect those of Aujoulat et al.'s study  
316 (Aujoulat, Marcolongo, Bonadiman, & Deccache, 2008), in which chronically ill

patients described a process through which they managed to resolve their identities as 'people living with a disease', not as 'diseased people'. Aujoulat et al. describe the processes through which individuals come to terms with a disrupted 'well' or 'normal' identity, manage the threat to their security and identity which illness represents, and face the lack of coherence or meaning which often accompanies diagnosis (Aujoulat et al., 2008). This reflects our own data and the wider HIV literature, which highlights that resistance for PLWH involves re-negotiating control over health and illness (Brinsdon, Abel, & Desrosiers, 2017; Goudge et al., 2009).

Our findings suggest that healthcare systems can play a role both in perpetuating and alleviating HIV-associated stigma. Research from South Africa also describes how women attending health care settings appreciated positive interactions with staff, while negative experiences further stigmatised (Okoror, BeLue, Zungu, Adam, & Airhihenbuwa, 2014). Recent research from Bangladesh demonstrates how a sexual and reproductive health rights training package administered to health care workers can reduce the stigma experienced by their patients. This study found that indicators of HIV-associated stigma among healthcare workers were reduced, alongside an increase in patient satisfaction with services (Geibel et al., 2017). In our study, the participants witnessed a working example of supportive, stigma-free care, and help to manage stigma through the provision of space to disclose and discuss openly.

An alternative explanation for the shift we observed in how participants felt could be that participants adjusted to their diagnosis over time. However, this sample of participants had been diagnosed with HIV for a median of 3.5 years (IQR 1.3-5.2) and had been on ART for a median of 2.5 years (IQR 0.8-4.2), therefore it is unlikely that this is the sole explanation. It might also be that the intervention itself, rather



than trial participation, improved stigma resistance. However, the striking similarity between the changes described by both control and intervention arm participants suggests otherwise. There was no contamination in the trial; control arm participants were seen by different clinical nurses. Additionally, the participants repeatedly referred to 'you' (addressing the researcher) as the one who had helped them.

A limitation of the study is that the concept of stigma emerged as an inductive theme during data analysis rather than being explored explicitly in the topic guides. Data on the experience of stigma and response to stigma was therefore not collected from all participants. However, despite this, stigma was a key feature of many patients' experiences of trial participation, described by 25 of the 30 participants. Another limitation is that, due to the inclusion criteria for the wider trial, the findings represent the experiences of PLWH who have been on ART for more than a month and are experiencing non-acute moderate to severe pain or other symptoms. However, this does not negate the importance of the experiences of this patient group. Since interviews were conducted by the same researcher who implemented the study, some social desirability bias is possible. We chose to keep the same researcher for both study components because of her experience and skill in conducting palliative care research, as we believe this skill outweighed any potential bias. Finally, the qualitative interviews necessarily took place after the trial had finished and so could be affected by recall bias.

Our findings have direct implications for clinical care and research for HIV communities, highlighting the association between psychosocial care and increased resistance to HIV-associated stigma. Failing to tackle stigma is a significant threat to infection control, access to testing, adequate treatment, and healthcare utilisation. Stakeholders at all levels of HIV care provision should consider the potential effects

of increasing levels of compassion, communication and social support in the care they provide to help PLWH resist stigma. It may be possible to integrate this approach into other, more established roles that are included in recommendations for best practice, such as treatment navigators or peer educators (Simoni, Pantalone, Plummer, & Huang, 2007; Thompson et al., 2012).

Future research is needed to explore whether the hypothesised shame resistance mechanisms of connecting, refocusing, accepting, understanding and resisting do indeed contribute to stigma resistance in PLWHA. Stigma should also be measured using a standardised outcome measure such as the PLWH Stigma Index, adapted and validated in each cultural setting, to enable cross-study and cross-country comparison and service evaluation (dos Santos, Kruger, Mellors, Wolvaardt, & van der Ryst, 2014; International Planned Parenthood Federation, 2008).

The findings also have implications for researchers working with socially isolated or stigmatised groups, who should consider the beneficial effects of participating in research, which may be in addition to any overt therapeutic input, in study design. This has been discussed more fully elsewhere (Lowther et al., 2016).

Resistance to HIV-associated stigma is possible, and can be encouraged through compassionate communication and social support. If these findings can be replicated at a larger scale and in different contexts, this affordable and life-affirming approach could have considerable public health and clinical significance for management of the HIV pandemic.

### *Funding*

This work was supported by the Diana Princess of Wales Memorial Fund.

## References:

- Adewuya, A. O., Afolabi, M. O., Ola, B. A., Ogundele, O. A., Ajibare, A. O., Oladipo, B. F., & Fakande, I. (2009). Post-traumatic stress disorder (PTSD) after stigma related events in HIV infected individuals in Nigeria. *Social Psychiatry and Psychiatric Epidemiology*, 44(9), 761–766.  
<https://doi.org/10.1007/s00127-009-0493-7>
- Aujoulat, I., Marcolongo, R., Bonadiman, L., & Deccache, A. (2008). Reconsidering patient empowerment in chronic illness: A critique of models of self-efficacy and bodily control. *Social Science & Medicine*, 66(5), 1228–1239.  
<https://doi.org/10.1016/j.socscimed.2007.11.034>
- Barbour, R. (2013). *Introducing Qualitative Research: A Student's Guide*. SAGE.
- Bennett, D. S., Traub, K., Mace, L., Juarascio, A., & O'Hayer, C. V. (2016). Shame among people living with HIV: a literature review. *AIDS Care*, 28(1), 87–91.  
<https://doi.org/10.1080/09540121.2015.1066749>
- Bogart, L. M., Chetty, S., Giddy, J., Sypek, A., Sticklor, L., Walensky, R. P., ... Bassett, I. V. (2013). Barriers to care among people living with HIV in South Africa: Contrasts between patient and healthcare provider perspectives. *AIDS Care*, 25(7), 843–853. <https://doi.org/10.1080/09540121.2012.729808>
- Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. *Qualitative Research in Psychology*, 3, 77–101.
- Brent, R. J. (2016). The value of reducing HIV stigma. *Social Science & Medicine*, 151, 233–240. <https://doi.org/10.1016/j.socscimed.2016.01.014>
- Brinsdon, A., Abel, G., & Desrosiers, J. (2017). 'I'm taking control': how people living with HIV/AIDS manage stigma in health interactions. *AIDS Care*, 29(2), 185–188. <https://doi.org/10.1080/09540121.2016.1204420>

415 Campbell, C., & Deacon, H. (2006). Unravelling the contexts of stigma: from  
 416 internalisation to resistance to change. *Journal of Community & Applied*  
 417 *Social Psychology*, 16(6), 411–417.

418 Campbell, C., Foulis, C. A., Maimane, S., & Sibiya, Z. (2005). ‘I have an evil child at  
 419 my house’: stigma and HIV/AIDS management in a South African community.  
 420 *Am J Public Health*, 95(5), 808–15. <https://doi.org/10.2105/ajph.2003.037499>

421 Dapaah, J. M., & Senah, K. A. (2016). HIV/AIDS clients, privacy and confidentiality;  
 422 the case of two health centres in the Ashanti Region of Ghana. *BMC Medical*  
 423 *Ethics*, 17, 41. <https://doi.org/10.1186/s12910-016-0123-3>

424 Dasgupta, S., Sullivan, P. S., Dasgupta, A., Saha, B., & Salazar, L. F. (2013). Stigma  
 425 and access to HIV care among HIV-infected women in Kolkata, West Bengal.  
 426 *Journal of the International Association of Providers of AIDS Care*, 12(1), 44–  
 427 49. <https://doi.org/http://dx.doi.org/10.1177/1545109711401410>

428 dos Santos, M. M., Kruger, P., Mellors, S. E., Wolvaardt, G., & van der Ryst, E.  
 429 (2014). An exploratory survey measuring stigma and discrimination  
 430 experienced by people living with HIV/AIDS in South Africa: the people living  
 431 with HIV stigma index. *BMC Public Health*, 14(1), 80.

432 Geibel, S., Hossain, S. M. I., Pulerwitz, J., Sultana, N., Hossain, T., Roy, S., ... Yam,  
 433 E. (2017). Stigma Reduction Training Improves Healthcare Provider Attitudes  
 434 Toward, and Experiences of, Young Marginalized People in Bangladesh.  
 435 *Journal of Adolescent Health*, 60(2, Supplement 2), S35–S44.  
 436 <https://doi.org/10.1016/j.jadohealth.2016.09.026>

437 Goffman, E. (1963). *Stigma. Notes on the management of spoiled identity*. New  
 438 Jersey, USA: Prentice-Hall.

439 Goudge, J., Ngoma, B., Manderson, L., & Schneider, H. (2009). Stigma, identity and  
 440 resistance among people living with HIV in South Africa. *SAHARA J*, 6(3), 94–  
 441 104.

442 Harding, R., Selman, L., Agupio, G., Dinat, N., Downing, J., Gwyther, L., ...  
 443 Higginson, I. J. (2010). Validation of a core outcome measure for palliative  
 444 care in Africa: the APCA African Palliative Outcome Scale. *Health & Quality of*  
 445 *Life Outcomes*, 8, 10. <https://doi.org/10.1186/1477-7525-8-10>

446 Herek, G. M., Saha, S., & Burack, J. (2013a). Stigma and Psychological Distress in  
 447 People With HIV/AIDS. *Basic and Applied Social Psychology*, 35(1), 41–54.  
 448 <https://doi.org/10.1080/01973533.2012.746606>

449 Herek, G. M., Saha, S., & Burack, J. (2013b). Stigma and Psychological Distress in  
 450 People With HIV/AIDS. *Basic and Applied Social Psychology*, 35(1), 41–54.  
 451 <https://doi.org/10.1080/01973533.2012.746606>

452 International Planned Parenthood Federation, U. (2008). *The people living with HIV*  
 453 *stigma index*. London: IPPF. Retrieved from  
 454 [http://www.stigmaindex.org/90/publications/the-people-living-with-hiv-stigma-](http://www.stigmaindex.org/90/publications/the-people-living-with-hiv-stigma-index-user-guide.html)  
 455 [index-user-guide.html](http://www.stigmaindex.org/90/publications/the-people-living-with-hiv-stigma-index-user-guide.html)

456 Ivankova, N. V., Creswell, J. W., & Stick, S. L. (2006). Using Mixed-Methods  
 457 Sequential Explanatory Design: From Theory to Practice. *Field Methods*,  
 458 18(1), 3–20. <https://doi.org/10.1177/1525822X05282260>

459 Lowther, K., Harding, R., Ahmed, A., Gikaara, N., Ali, Z., Kariuki, H., ... Selman, L.  
 460 (2016). Conducting experimental research in marginalised populations:  
 461 clinical and methodological implications from a mixed-methods randomised  
 462 controlled trial in Kenya. *AIDS Care*, 28(sup1), 60–63.  
 463 <https://doi.org/10.1080/09540121.2016.1146214>

464 Lowther, K., Higginson, I. J., Simms, V., Gikaara, N., Ahmed, A., Ali, Z., ... Harding,  
 465 R. (2014). A randomised controlled trial to assess the effectiveness of a  
 466 nurse-led palliative care intervention for HIV positive patients on antiretroviral  
 467 therapy: recruitment, refusal, randomisation and missing data. *BMC Research*  
 468 *Notes*, 7(1), 600. <https://doi.org/10.1186/1756-0500-7-600>  
 469 Lowther, K., Selman, L., Simms, V., Gikaara, N., Ahmed, A., Ali, Z., ... Harding, R.  
 470 (2015). Nurse-led palliative care for HIV-positive patients taking antiretroviral  
 471 therapy in Kenya: a randomised controlled trial. *The Lancet HIV*, 2(8), e328–  
 472 e334. [https://doi.org/10.1016/S2352-3018\(15\)00111-3](https://doi.org/10.1016/S2352-3018(15)00111-3)  
 473 Lowther, K., Simms, V., Selman, L., Sherr, L., Gwyther, L., Kariuki, H., ... Harding,  
 474 R. (2012). Treatment outcomes in palliative care: the TOPCare study. A  
 475 mixed methods phase III randomised controlled trial to assess the  
 476 effectiveness of a nurse-led palliative care intervention for HIV positive  
 477 patients on antiretroviral therapy. *BMC Infectious Diseases*, 12, 288.  
 478 <https://doi.org/10.1186/1471-2334-12-288>  
 479 Mbonu, N. C., van den Borne, B., & De Vries, N. K. (2009). Stigma of people with  
 480 HIV/AIDS in Sub-Saharan Africa: a literature review. *Journal of Tropical*  
 481 *Medicine*, 2009.  
 482 Mhode, M., & Nyamhanga, T. (2016). Experiences and Impact of Stigma and  
 483 Discrimination among People on Antiretroviral Therapy in Dar es Salaam: A  
 484 Qualitative Perspective. *AIDS Research and Treatment*, 2016, e7925052.  
 485 <https://doi.org/10.1155/2016/7925052>  
 486 Miller, C. T., Solomon, S. E., Varni, S. E., Hodge, J. J., Knapp, F. A., & Bunn, J. Y.  
 487 (2016). A transactional approach to relationships over time between perceived  
 488 HIV stigma and the psychological and physical well-being of people with HIV.

489           *Social Science & Medicine*, 162, 97–105.

490           <https://doi.org/10.1016/j.socscimed.2016.06.025>

491   Nyblade, L., Pande, R., Mathur, S., MacQuarrie, K., Kidd, R., Banteyerga, H., ...

492           Bond, V. (2003). Disentangling HIV and AIDS stigma in Ethiopia, Tanzania

493           and Zambia.

494   Okoror, T. A., BeLue, R., Zungu, N., Adam, A. M., & Airhihenbuwa, C. O. (2014). HIV

495           Positive Women's Perceptions of Stigma in Health Care Settings in Western

496           Cape, South Africa. *Health Care for Women International*, 35(1), 27–49.

497           <https://doi.org/10.1080/07399332.2012.736566>

498   Owolabi, R. S., Araoye, M. O., Osagbemi, G. K., Odeigah, L., Ogundiran, A., &

499           Hussain, N. A. (2012). Assessment of stigma and discrimination experienced

500           by people living with HIV and AIDS receiving care/treatment in University of

501           Ilorin Teaching Hospital (UITH), Ilorin, Nigeria. *Journal of the International*

502           *Association of Physicians in AIDS Care*, 11(2), 121–127.

503           <https://doi.org/http://dx.doi.org/10.1177/1545109711399443>

504   Palmer, A. K., Duncan, K. C., Ayalew, B., Zhang, W., Tzemis, D., Lima, V., ... Hogg,

505           R. S. (2011). 'The way I see it': the effect of stigma and depression on self-

506           perceived body image among HIV-positive individuals on treatment in British

507           Columbia, Canada. *AIDS Care*, 23(11), 1456–66.

508           <https://doi.org/http://dx.doi.org/10.1080/09540121.2011.565021>

509   Parker, R., & Aggleton, P. (2003). HIV and AIDS-related stigma and discrimination: a

510           conceptual framework and implications for action. *Soc Sci Med*, 57(1), 13–24.

511   Sandelowski, M. (1995). Sample size in qualitative research. *Research in Nursing &*

512           *Health*, 18(2), 179–183.

513 Sengupta, S., Banks, B., Jonas, D., Miles, M. S., & Smith, G. C. (2011). HIV  
514 interventions to reduce HIV/AIDS stigma: a systematic review. *AIDS Behav*,  
515 15(6), 1075–87. <https://doi.org/10.1007/s10461-010-9847-0>

516 Simoni, J. M., Pantalone, D. W., Plummer, M. D., & Huang, B. (2007). A  
517 Randomized Controlled Trial of a Peer Support Intervention Targeting  
518 Antiretroviral Medication Adherence and Depressive Symptomatology in HIV-  
519 Positive Men and Women. *Health Psychology*, 26(4), 488–495.  
520 <https://doi.org/http://dx.doi.org/10.1037/0278-6133.26.4.488>

521 Soskolne, T. (2003). *Moving beyond the margins: A narrative analysis of the life*  
522 *stories of women living with HIV/AIDS in Khayelitsha* (Report No. CSSR  
523 Working Paper No. 33). Centre for Social Research, University of Cape Town.  
524 Retrieved from <http://www.uct.ac.za/depts/cssr/pubs.html>

525 Stangl, A. L., & Grossman, C. I. (2013). Global Action to reduce HIV stigma and  
526 discrimination. *Journal of the International AIDS Society*, 16(3Suppl 2).

527 Stangl, A. L., Lloyd, J. K., M Brady, L., Holland, C. E., & Baral, S. (2013). A  
528 systematic review of interventions to reduce HIV-related stigma and  
529 discrimination from 2002 to 2013: how far have we come? *Journal of the*  
530 *International AIDS Society*, 16(3(Suppl 2)).  
531 <https://doi.org/10.7448/IAS.16.3.18734>

532 Sumari-de Boer, I., Sprangers, M. A., Prins, J. M., & Nieuwkerk, P. T. (2012). HIV  
533 stigma and depressive symptoms are related to adherence and virological  
534 response to antiretroviral treatment among immigrant and indigenous HIV  
535 infected patients. *AIDS and Behavior*, 16(6), 1681–1689.  
536 <https://doi.org/http://dx.doi.org/10.1007/s10461-011-0112-y>



- Sweeney, S. M., & Venable, P. A. (2016). The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature. *AIDS and Behavior*, 20(1), 29–50. <https://doi.org/10.1007/s10461-015-1164-1>
- Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., ... Nachega, J. B. (2012). Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel. *Annals of Internal Medicine*, 156(11), 817. <https://doi.org/10.7326/0003-4819-156-11-201206050-00419>
- Turan, J. M., & Nyblade, L. (2013). HIV-related stigma as a barrier to achievement of global PMTCT and maternal health goals: a review of the evidence. *AIDS and Behavior*, 17(7), 2528–2539.
- Van Vliet, K. J. (2008). Shame and resilience in adulthood: A grounded theory study. *Journal of Counseling Psychology*, 55(2), 233.
- Visser, M., & Sipsma, H. (2013). The experience of HIV-related stigma in South Africa. In *Stigma, Discrimination and Living with HIV/AIDS* (pp. 205–227). Springer.
- WHO. (2013). *WHO definition of Palliative Care*. WHO. Retrieved from <http://www.who.int/cancer/palliative/definition/en/>
- Wu, A. W. (1999). *MOS-HIV Health Survey. Users Manual*. Johns Hopkins University. Retrieved from <http://chipts.cch.ucla.edu/assessment/pdf/assessments/MOS-HIV%20Users%20Manual%20%20Draft.pdf>



Table 1 Clinical and demographic characteristics of the sample (n=30)

Mean age (years, sd)	39.1 (6.9)
Gender (% female)	80%
Partner status , yes N (%)	17 (56.7%)
Number of children	
Mean (sd)	2.4 (1.4)
Median (IQR)	2 (2-3)
Number of financial dependents	
Mean (sd)	3.2 (2.0)
Median (IQR)	3 (2-4)
Education attainment N (%)	
None	3 (10.0%)
4 years or less	2 (6.7%)
Primary education	15 (50.0%)
Secondary education	10 (33.3%)
Diploma	0 (0%)
CD4 count at baseline, Mean (sd)	348.13 (273.75)
Receiving TB treatment? Yes n (%)	5 (16.6%)
Received an AIDS diagnosis? Yes n (%)	30 (100%)
Owens a bicycle? Yes n (%)	8 (26.7%)
Owens a fridge? Yes n (%)	7 (23.3%)
Owens a television? Yes n (%)	18 (60%)
Owens a car? Yes n (%)	2 (6.7%)
Owens a radio? Yes n (%)	18 (60%)

Mental health summary score change on MOS-HIV MHSS	Control n(%)	Intervention n(%)
Improving (increase of 10 points)	6 (60%)	14 (70%)
Deteriorating (decrease of 10 points)	0 (0%)	1 (5%)
Static (no change of 10 points or more)	4 (40%)	5 (25%)

564

565

Table 2 Experience of HIV-associated stigma

Quote number	Quote
1	“Initially, I had a lot of [hesitates] ... friends, but when I knew about my status I started fearing them – because I feared they [hesitates] might be discussing about me”. <i>Woman, age 28, intervention arm ID 126</i>
2	“I was so afraid because in my entire life I never thought this disease would get me. I knew it was meant for some people with immoral behaviours within the community and I was living a straight upright life, even without a degree education.” <i>Woman, 33 years, control arm ID 158</i>
3	“[They said:] ‘You went and took your own illness. I told [you about] your husband - leave him, he will infect you with that illness, he likes a lot of women - now you see? Now you see?’” <i>Woman, 40 years, control arm ID 133</i>
4	“The way they used to talk about me, that I have this illness, and then they started isolating me. At first we were together but when they knew I had that illness they started isolating me, and that brought on the thoughts. When I look around, I can’t find any companion.” <i>Woman, 40 years, control arm ID 133</i>

Table 3 Effects of participation in the study

Quote number	Quote
5	“Yeah, based on how we started, the way you showed me the importance, you enlightened me about this condition and the importance of my life. This made me to change and go back to my normal state and be like any other person.” <i>Woman, 39 years, intervention arm ID 106</i>
6	“When you used to ask me questions, I used to feel much free inside ... I felt like a very normal person without any form of illness, I felt so good eh”. <i>Woman, 54 years, intervention arm ID 126</i>
7	“I started viewing myself like any other person, as you see me now, like am not sick at all. I stopped worrying about myself and focused.” <i>Woman, 43 years, intervention arm ID 129</i>
8	“...because thinking back when I used to be so ill, I saw it wise to kill myself with a rat poison [laughing], mixing it with a glass of water and drink it all [laughing] ... because there was no need staying on earth’s surface in so much pain and suffering, at times I felt like hanging myself... when I started coming here you [nurses] started advising me... since then I have been so close to God and never had a bad thought again. ... I dumped the rat poison in a pit latrine.” <i>Woman, 43 years, intervention arm ID 129</i>
9	“I used to be soothed, such as being treated well, I mean I felt esteemed, that people here regarded me and treated me with respect”. <i>Woman, 39 years, intervention arm ID 106</i>
10	“Now, I didn’t have anyone to talk to or someone to ask me, “How are you feeling, what do you think or how are you doing?” So when I came here I feel it really helped me because I found ... [hesitates] that day, I found people who were

	very free and they talked to me very nicely. The way I was received – I really appreciate.” <i>Woman, 46 years, control arm ID 107</i>
11	“What I’d want to say is to appreciate you [the interviewer] for the service that I received here. I was treated so well till I started feeling like I’m really a human being. Indeed, this is place where you are treated with dignity to the point of appreciating yourself.” <i>Man, 44 years, intervention arm ID 123</i>
12	“So many things have contributed to these changes, but the greatest of all is me accepting myself in this condition and appreciating that this is my new way of life; another thing is the way you handle patients. For instance, one may come here broken hearted and feeling down but you would encourage and give him the best so many things contributed to this change.” <i>Woman 33 years, control arm ID 158</i>
13	“It has changed my thought, cleared my mind and my feelings also, I felt like one who matters in the society... I have changed and [the experience of participating in the study] made to accept myself as I am. It made my heart stronger and I proceeded on with my normal life.” <i>Woman 50 years, intervention arm ID 135</i>
14	“I had understood and accepted myself as I am; I was never ashamed any more but rather very open.” <i>Man, 43 years, control arm ID 97</i>
15	“I was only close to my brother amongst my family members and because I wasn’t open to him either, we never had a good relationship but during the study I changed. I could go to his house and explain my condition to him care free. So, our relationship has revived and we are free to each other.” <i>Woman, 33 years, control arm ID 158</i>
16	“The first advice I received when they diagnosed me to be positive they told me that, “mum you have the virus and you don’t need to panic in front of people because they will realize you have it, all you need to do is behave normally, don’t

	behave awkwardly and get rid of all the worries.” <i>Woman, 54 years, intervention arm ID 126</i>
17	“The most important thing was ... being able to express myself. To accept what has become of me and to say that this is what is happening but I can overcome it. This has been very nice and then a forum of expressing my innermost feelings and fears.” <i>Woman, 41 years, intervention arm ID 134</i>
18	“I just love the way I was being questioned in a polite tone that made me to open up my heart. I love the way you handle me in a friendly nice way.” <i>Woman, 33 years, control arm ID 159</i>
19	“You helped by asking me several questions on what was affecting [me], I felt like someone was helping me to carry my burden.” <i>Woman, 42 years, control, ID 130</i>
20	“It also helped me because when I started going there I used to be afraid but after coming here and got to be asked the questions, I started answering expressly, I found it to be of much help because I started feeling free.” <i>Woman, 46 years, control arm ID 107</i>
21	“[Participating] gave me the courage even to stand in front of anyone to share with them about myself.... I have a very good relationship [with those in my community] because I have disclosed my status to them. They have even nicknamed me – you know me as [name] they call me a minister. And do you know it’s a minister in charge of what? Minister for viruses! And I have accepted it.” <i>Woman, 36 years, control arm, ID 143</i>
22	I was scared when I first started this study, and my health was also not in a good condition when I started but as I came here for the discussions I started feeling ok, because I became free and started living my life as normal and when I told my



	family about my health, they also joined hands in supporting me.” <i>Woman 50 years, intervention arm ID 135</i>
23	“About my experience here, let me say that you people helped me a lot, because right now I can go out and tell or teach someone or approach someone, telling them to go and know their statuses. .... Never mind they’re the very, same people who were speaking ill about me. Yeah and I still reach out to them, counselling them and once they agree, I take them up to there [to the hospital to test for HIV]”. <i>Female, 36 years, control arm ID 143</i>

573

574

575

576

577

578

579